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BACKGROUND: Although real-life results of sofosbuvir/simeprevir have been
extensively reported from the United States, data from other geographical areas are
limited. In the French observational cohort, ANRS CO22 HEPATHER, 9432 patients
were given the new oral antivirals from December 2013 to June 30, 2018. We report
the results of sofosbuvir/simeprevir in genotypes 1- and 4-infected patients.
METHODS: Demographics and history of liver disease were collected at entry in the
cohort. Clinical, adverse events, and virological data were collected throughout
treatment and post-treatment follow-up. The choice of treatment duration or addition
of ribavirin was left up to the physician.
RESULTS: Five hundred ninety-nine HCV (467 genotype 1 and 132 genotype 4) mono-
infected, naïve for all oral-DAAs regimen patients were given sofosbuvir/simeprevir
with (n = 63) or without ribavirin (n = 536) for 12 or 24 weeks; 56% had cirrhosis (4%
decompensated) and 71% had prior treatment failure to interferon-based regimen. 7
patients (1.16%) were lost to follow-up. The overall SVR12 rate was 92.6%. The SVR12
was 90% in GT1a, 94.2% in GT1b and 91.6% in GT4 with no significant difference for
genotype, treatment duration or ribavirin addition. Severity of liver disease was not
associated with a lower SVR12 rate on multivariate analysis but was associated with a
higher rate of severe side effects. Early treatment discontinuations were rare; no new
safety signals were reported.
CONCLUSION: In this real life, observational, prospective cohort study, the 12-week
sofosbuvir/simeprevir+/-ribavirin combination appears to be efficient and safe.
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